Proglucagon processing in porcine and human pancreas

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Proglucagon processing in porcine and human pancreas. / Holst, J J; Bersani, M; Johnsen, A H; Kofod, Hans; Hartmann, B; Orskov, C.

In: Journal of Biological Chemistry, Vol. 269, No. 29, 1994, p. 18827-33.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Holst, JJ, Bersani, M, Johnsen, AH, Kofod, H, Hartmann, B & Orskov, C 1994, 'Proglucagon processing in porcine and human pancreas', Journal of Biological Chemistry, vol. 269, no. 29, pp. 18827-33.

APA

Holst, J. J., Bersani, M., Johnsen, A. H., Kofod, H., Hartmann, B., & Orskov, C. (1994). Proglucagon processing in porcine and human pancreas. Journal of Biological Chemistry, 269(29), 18827-33.

Vancouver

Holst JJ, Bersani M, Johnsen AH, Kofod H, Hartmann B, Orskov C. Proglucagon processing in porcine and human pancreas. Journal of Biological Chemistry. 1994;269(29):18827-33.

Author

Holst, J J ; Bersani, M ; Johnsen, A H ; Kofod, Hans ; Hartmann, B ; Orskov, C. / Proglucagon processing in porcine and human pancreas. In: Journal of Biological Chemistry. 1994 ; Vol. 269, No. 29. pp. 18827-33.

Bibtex

@article{324d5c5074cd11dbbee902004c4f4f50,
title = "Proglucagon processing in porcine and human pancreas",
abstract = "In the pancreas proglucagon (PG), a peptide precursor of 160 amino acids is cleaved to produce glucagon and a 30-amino acid N-terminal flanking peptide, but the fate of the C-terminal flanking peptide (99 amino acids) is incompletely known. We subjected acid ethanol extracts of human and porcine pancreases to gel filtration and analyzed the fractions with specific radioimmunoassays for the following regions of proglucagon: PG 62-69, PG 72-81, PG 78-87, PG 98-107 amide, PG 126-134, and PG 149-158. Based on these assays and successive purifications by high performance liquid chromatography we isolated and purified to homogeneity three porcine peptides which were subjected to mass spectrometry and sequencing. One peptide was PG 64-69. The second was PG 72-108, as determined by mass spectrometry, N-terminal amino acid sequencing, and specific radioimmunoassays. The third had a molecular size of approximately 10,000, an N-terminal sequence corresponding to PG 72-81, and a C-terminal sequence terminating at PG 158 (specific radioimmunoassay). A similar peptide with an identical N-terminal sequence, a C-terminal sequence corresponding to PG 146-158, and a molecular mass of 9969 (theoretical mass for human PG 72-158 = 9971) was isolated from human pancreas together with small amounts of a peptide corresponding to PG 72-107 amide. Thus, the pancreatic processing of the C-terminal flanking peptide in proglucagon includes the formation of equimolar (to glucagon) amounts of PG 64-69 and PG 72-158 (major proglucagon fragment) and smaller amounts of N-terminally extended glucagon-like peptide-1 (GLP-1) (PG 72-108 in pigs and PG 72-107 amide in humans).",
keywords = "Amino Acid Sequence, Animals, Glicentin, Glucagon, Glucagon-Like Peptides, Humans, Molecular Sequence Data, Pancreas, Peptide Fragments, Proglucagon, Protein Precursors, Protein Processing, Post-Translational, Swine",
author = "Holst, {J J} and M Bersani and Johnsen, {A H} and Hans Kofod and B Hartmann and C Orskov",
year = "1994",
language = "English",
volume = "269",
pages = "18827--33",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology, Inc.",
number = "29",

}

RIS

TY - JOUR

T1 - Proglucagon processing in porcine and human pancreas

AU - Holst, J J

AU - Bersani, M

AU - Johnsen, A H

AU - Kofod, Hans

AU - Hartmann, B

AU - Orskov, C

PY - 1994

Y1 - 1994

N2 - In the pancreas proglucagon (PG), a peptide precursor of 160 amino acids is cleaved to produce glucagon and a 30-amino acid N-terminal flanking peptide, but the fate of the C-terminal flanking peptide (99 amino acids) is incompletely known. We subjected acid ethanol extracts of human and porcine pancreases to gel filtration and analyzed the fractions with specific radioimmunoassays for the following regions of proglucagon: PG 62-69, PG 72-81, PG 78-87, PG 98-107 amide, PG 126-134, and PG 149-158. Based on these assays and successive purifications by high performance liquid chromatography we isolated and purified to homogeneity three porcine peptides which were subjected to mass spectrometry and sequencing. One peptide was PG 64-69. The second was PG 72-108, as determined by mass spectrometry, N-terminal amino acid sequencing, and specific radioimmunoassays. The third had a molecular size of approximately 10,000, an N-terminal sequence corresponding to PG 72-81, and a C-terminal sequence terminating at PG 158 (specific radioimmunoassay). A similar peptide with an identical N-terminal sequence, a C-terminal sequence corresponding to PG 146-158, and a molecular mass of 9969 (theoretical mass for human PG 72-158 = 9971) was isolated from human pancreas together with small amounts of a peptide corresponding to PG 72-107 amide. Thus, the pancreatic processing of the C-terminal flanking peptide in proglucagon includes the formation of equimolar (to glucagon) amounts of PG 64-69 and PG 72-158 (major proglucagon fragment) and smaller amounts of N-terminally extended glucagon-like peptide-1 (GLP-1) (PG 72-108 in pigs and PG 72-107 amide in humans).

AB - In the pancreas proglucagon (PG), a peptide precursor of 160 amino acids is cleaved to produce glucagon and a 30-amino acid N-terminal flanking peptide, but the fate of the C-terminal flanking peptide (99 amino acids) is incompletely known. We subjected acid ethanol extracts of human and porcine pancreases to gel filtration and analyzed the fractions with specific radioimmunoassays for the following regions of proglucagon: PG 62-69, PG 72-81, PG 78-87, PG 98-107 amide, PG 126-134, and PG 149-158. Based on these assays and successive purifications by high performance liquid chromatography we isolated and purified to homogeneity three porcine peptides which were subjected to mass spectrometry and sequencing. One peptide was PG 64-69. The second was PG 72-108, as determined by mass spectrometry, N-terminal amino acid sequencing, and specific radioimmunoassays. The third had a molecular size of approximately 10,000, an N-terminal sequence corresponding to PG 72-81, and a C-terminal sequence terminating at PG 158 (specific radioimmunoassay). A similar peptide with an identical N-terminal sequence, a C-terminal sequence corresponding to PG 146-158, and a molecular mass of 9969 (theoretical mass for human PG 72-158 = 9971) was isolated from human pancreas together with small amounts of a peptide corresponding to PG 72-107 amide. Thus, the pancreatic processing of the C-terminal flanking peptide in proglucagon includes the formation of equimolar (to glucagon) amounts of PG 64-69 and PG 72-158 (major proglucagon fragment) and smaller amounts of N-terminally extended glucagon-like peptide-1 (GLP-1) (PG 72-108 in pigs and PG 72-107 amide in humans).

KW - Amino Acid Sequence

KW - Animals

KW - Glicentin

KW - Glucagon

KW - Glucagon-Like Peptides

KW - Humans

KW - Molecular Sequence Data

KW - Pancreas

KW - Peptide Fragments

KW - Proglucagon

KW - Protein Precursors

KW - Protein Processing, Post-Translational

KW - Swine

M3 - Journal article

C2 - 8034635

VL - 269

SP - 18827

EP - 18833

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 29

ER -

ID: 243108